GlassScriptPhysician profile
Jean Davis
NPI 1801294756
$8,645.73
in general payments reported to CMS, 2019-2025
21 companies · $1,157 in 2025
The $1,157 reported for 2025 was more than what 89% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,332 · 2022: $1,390 · 2023: $1,714 · 2024: $3,051 · 2025: $1,157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,323 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,322.95 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $600.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,392.34 | 2021-2025 | |
| Gilead Sciences, INC. | $1,704.82 | 2021-2025 | Epclusa, Vemlidy |
| Janssen Biotech, INC. | $1,145.91 | 2021-2025 | Stelara, Tremfya |
| Pfizer INC. | $722.89 | 2023-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $635.84 | 2021-2025 | Xifaxan, Trulance |
| Organon LLC | $542.85 | 2021-2025 | Renflexis, Hadlima |
| Takeda Pharmaceuticals U.S.A., INC. | $435.99 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Intercept Pharmaceuticals, INC. | $250.22 | 2021-2025 | Ocaliva |
| Madrigal Pharmaceuticals | $129.99 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $120.65 | 2023-2024 | Omvoh |
| Genzyme Corporation | $110.25 | 2022-2024 | |
| Ipsen Biopharmaceuticals, INC | $108.53 | 2023-2025 | Bylvay, Iqirvo |
| Orphalan INC | $84.28 | 2023-2024 | Cuvrior |
| Merck Sharp & Dohme LLC | $52.89 | 2023 | Dificid |
| Albireo Pharma, INC. | $44.28 | 2024 | Iqirvo |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Napo Pharmaceuticals INC | $38.97 | 2025 | Mytesi |
| Qol Medical, LLC | $36.66 | 2022 | |
| Mirum Pharmaceuticals, INC. | $34.44 | 2025 | Livmarli |
| Astrazeneca Pharmaceuticals LP | $31.57 | 2025 | Calquence |
| Redhill Biopharma INC. | $13.40 | 2023 | Talicia |
| Janssen Scientific Affairs, LLC | $8.96 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jean Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.